

David Power MBBCh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4985504/publications.pdf>

Version: 2024-02-01

16
papers

185
citations

1163117

8
h-index

1125743

13
g-index

16
all docs

16
docs citations

16
times ranked

275
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 20-29.	2.1	8
2	Outcomes of intravascular ultrasound versus optical coherence tomography guided percutaneous coronary angiography: A meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, .	1.7	6
3	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 557-567.	3.0	20
4	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. <i>International Journal of Cardiology</i> , 2021, 322, 65-69.	1.7	3
5	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E704-E715.	1.7	8
6	Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1387-1396.	1.7	42
7	A Personalized Approach to Chronic Kidney Disease and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1470-1479.	2.8	28
8	Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E870-E880.	1.7	2
9	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E785-E795.	1.7	2
10	Coronary Dissection and Right Heart Failure Salvaged by PCI With Percutaneous Intraluminal Microaxial RV-Assist Support. <i>JACC: Case Reports</i> , 2021, 3, 1612-1616.	0.6	0
11	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2447-2457.	2.9	3
12	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E688-E694.	1.7	1
13	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. <i>International Journal of Cardiology</i> , 2019, 297, 22-29.	1.7	10
14	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	1.7	35
15	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 709-716.	1.6	9
16	Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 735-748.	1.5	8